Cellular Biology Research

🚀 The ADC Revolution: How "Biological Missiles" Are Transforming Cancer Antibody-drug conjugates (ADCs) are the precision-guided missiles of oncology—combining monoclonal antibodies, ultra-potent cytotoxic payloads, and smart linkers to deliver targeted destruction to cancer cells. With 15 FDA-approved ADCs and over 1,172 in development, this space is exploding—but what’s next? 🔥 Key Breakthroughs Changing the Game ➡️Breast Cancer: Enhertu (T-DXd) just secured FDA approval in 2025 after showing a 57.3% response rate (vs. 31.2% for chemo) in HER2-low metastatic breast cancer. ➡️Lung Cancer: T-DXd also shines in HER2-mutant NSCLC (38% response rate), while TROP2-targeted ADCs (like Datroway) extend survival in tough-to-treat cases. ➡️Dual-Payload ADCs: The next frontier—KH815 (TROP2 + dual payload) just entered Phase I, and 15+ others are in the pipeline, tackling resistance with two drugs in one. ⚙️ Tech Disruptions Driving Value ➡️Site-Specific Conjugation (e.g., Synaffix’s GlycoConnect™) is reducing toxicity—J&J and Boehringer just bet $1.3B on it. ➡️Beyond Chemo Payloads: STING agonists (Mersana Therapeutics), PROTAC degrades (DAC-Cullgen Inc.), and RNA disruptors (Heidelberg Pharma AG) are expanding ADC potential. ➡️Bispecific & Radioligand Hybrids: Imagine an ADC that also delivers radiation (Bayer/PeptiDream’s Ac-225 ADCs). 💡 Challenges = Investment Opportunities ❗️Manufacturing bottlenecks (auristatin shortages, 30-50% higher costs than mAbs). ❗️Toxicity management (interstitial lung disease, ocular effects). ❗️Regulatory hurdles (novel payloads add 12-18 months to the development process). 🌍 Beyond Oncology? ADCs are branching into autoimmune diseases ( Duality Biologics), chronic infections, and even brain disorders with BBB-penetrating designs (ABL Bio Inc. - ABL001). 💬 Let’s Discuss! Which ADC innovation excites you most—dual payloads, bispecifics, or non-chemo warheads? Can ADCs overcome manufacturing challenges to become first-line therapies? Which non-cancer application could be the next big market for ADCs? #biotechnology #investment #investor #drug #drugdevelopment #market #science #pharma #business #Biotech #VentureCapital #Investing #BusinessDevelopment #BD #investor _______________________________________________________________________________ 🔔 Follow for insights ♻️ Share to expand the network.

Pfizer turned a routine Phase 1 trial into a landmark lung cancer approval by doing one thing most sponsors avoid: They changed the trial mid-study. When crizotinib entered the clinic in 2006, it was designed as a c-MET inhibitor for advanced solid tumors. There was no lung cancer focus, no ALK-selected cohort, and no obvious precision oncology story. Then researchers discovered ALK fusions in a small subset of non-small cell lung cancer patients. Around the same time, crizotinib was shown to be a potent ALK inhibitor. Instead of finishing the original trial and starting over, Pfizer amended the ongoing study and added a biomarker-selected cohort of ALK-positive lung cancer patients. That decision changed everything. The enriched cohort produced a 57% objective response rate in a patient population that represented only about 5% of NSCLC. In 2011, crizotinib received FDA accelerated approval roughly five years after the first patient was dosed. Crizotinib proves that real-time signal detection, biomarker-driven enrollment, and protocol flexibility can turn an unexpected finding into a breakthrough therapy.

When a single cytokine explains why an entire NSCLC genotype is “inflamed but immune‑cold,” you have more than just another biomarker—you have a lever. In LKB1‑mutant lung adenocarcinoma, Pillai et al. dissect a tumor‑intrinsic LKB1–LIF–Sox17 axis that does three things at once: it drives dedifferentiation into a stem‑like, EMT‑like state, constructs an Arg1‑heavy myeloid niche, and silences CD4/CD8 T‑cell effector function. Anti‑LIF therapy doesn’t just shrink tumors; it erases that Sox17‑high state, collapses the immunosuppressive neutrophil/macrophage architecture, and makes T‑cell depletion matter again. With AZD0171 already in the clinic, LIF is no longer a theoretical node in an interesting pathway. It is a practical way to test whether we can convert an immune‑cold, LKB1‑mutant genotype into one that is finally permissive to checkpoint blockade—and to do it by editing the tumor’s dominant cell state, not just its bulk inflammation score.

🚀 Johnson & Johnson’s #RYBREVANT® + #LAZCLUZE® Delivers ~3.5-Year #Median #Overall #Survival in Atypical #EGFR-Mutated NSCLC, Reinforcing First-Line Leadership at #ASCO26 Johnson & Johnson reported updated Phase 1/1b CHRYSALIS-2 data showing RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) achieved median overall survival (OS) of 41 months (~3.5 years) in first-line atypical EGFR-mutated advanced NSCLC — a population historically associated with poor outcomes and limited treatment options. The data were presented at #ASCO26 and may meaningfully reshape expectations for atypical EGFR disease. 1️⃣ Why this matters: a difficult-to-treat NSCLC subgroup Atypical EGFR mutations represent roughly 10–20% of EGFR-mutated NSCLC, with many patients experiencing median survival under 2 years using conventional EGFR TKIs. In the CHRYSALIS-2 Cohort C trial (n=49): ✅ Median OS: 41.0 months (~3.5 years) ✅ 3-year OS: 55% ✅ 4-year OS: 46% ✅ Objective response rate (ORR): 57% Importantly, responses were observed across historically challenging mutation groups including: 📌 G719X (55%) 📌 S768X (27%) 📌 L861X (24%) 2️⃣ The science: dual-targeting EGFR + MET Unlike traditional single-pathway EGFR TKIs, RYBREVANT® is a bispecific antibody targeting both EGFR and MET, designed to address resistance biology from the start. According to Yusri Elsayed, MD, MHSc,PhD, Global Therapeutic Area Head, Oncology at Johnson & Johnson: RYBREVANT-based combinations aim to “change the biology” by addressing multiple disease drivers rather than relying on single-pathway strategies. Meanwhile, Joel Neal, M.D., Ph.D. of Stanford University School of Medicine, Principal Investigator of CHRYSALIS-2, highlighted the potential for more durable disease control in a setting where first-line treatment decisions often carry significant uncertainty. 3️⃣ Durability matters Notably: 📌 41% of patients remained on RYBREVANT® for ≥2 years 📌 Most adverse events were Grade 1–2 📌 No new safety signals emerged with longer follow-up 🧩 My takeaway For atypical EGFR-mutated NSCLC, this may represent a meaningful shift away from single-agent TKI thinking toward multi-target biology-driven treatment strategies. The biggest story is not just response rate — it’s durable survival in a historically underserved molecular subtype. 📌 Bottom line Johnson & Johnson’s #RYBREVANT® + #LAZCLUZE® achieved nearly 3.5-year median survival in atypical EGFR-mutated NSCLC, potentially raising the bar for first-line treatment in a high unmet-need lung cancer population. #ASCO26 #LungCancer #NSCLC #Oncology #PrecisionMedicine #Biotech #CancerResearch #JohnsonAndJohnson #EGFR #TargetedTherapy https://lnkd.in/gdMRnuAg

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the widespread use of the drug, we must deeply analyze the dilemma of the agents and seek a breakthrough in the treatment prospect. Over the past decades, these agents have demonstrated dramatic efficacy, especially in patients with melanoma and non-small cell lung cancer (NSCLC). Nonetheless, in the field of a broad concept of solid tumours, non-specific indications, inseparable immune response and side effects, unconfirmed progressive disease, and complex regulatory networks of immune resistance are four barriers that limit its widespread application. Fortunately, the successful clinical trials of novel ICB agents and combination therapies, the advent of the era of oncolytic virus gene editing, and the breakthrough of the technical barriers of mRNA vaccines and nano-delivery systems have made remarkable breakthroughs currently. In this review, we enumerate the mechanisms of each immune checkpoint targets, associations between ICB with tumour mutation burden, key immune regulatory or resistance signalling pathways, the specific clinical evidence of the efficacy of classical targets and new targets among different tumour types and put forward dialectical thoughts on drug safety. Finally, we discuss the importance of accurate triage of ICB based on recent advances in predictive biomarkers and diagnostic testing techniques. https://lnkd.in/ejimpwy6

Lung cancer is not one disease. It is many diseases hiding under one name. 🫁🧬 This is especially true for non-small cell lung cancer (NSCLC). For years, lung cancer treatment was mostly based on what the tumour looked like under a microscope. But now, molecular profiling is changing the game. Why? Because NSCLC can be driven by different genetic mutations — and each one can influence how the cancer grows, spreads, and responds to treatment. Some common mutations and alterations include: 🔹 KRAS — one of the most frequent drivers 🔹 EGFR — a major target in precision therapy 🔹 ALK — often treatable with targeted inhibitors 🔹 BRAF — involved in growth signalling pathways 🔹 MET — linked to tumour progression and resistance 🔹 HER2/ERBB2, RET, ROS1, NTRK, NRG1 — less common, but clinically important And then there is the “unknown” category — a reminder that cancer biology still has unanswered questions. What makes this so important is simple: The mutation matters. 🎯 Two patients can both have NSCLC, but their cancers may behave completely differently because the molecular drivers are different. That is why biomarker testing is so powerful. It helps move treatment from: ❌ “You have lung cancer, here is a general treatment.” to ✅ “Your tumur has this driver mutation, so we can choose a more precise strategy.” This is the heart of precision oncology. Not treating cancer by name alone. Treating cancer by its biology. 🧠✨ Every mutation tells a story. And in NSCLC, that story can guide the next step in treatment. #NSCLC #LungCancer #CancerResearch #PrecisionMedicine #Oncology #BiomarkerTesting #TargetedTherapy #EGFR #KRAS #ALK #CancerBiology #MedicalEducation #ScienceCommunication *Taken from BioRender for Educational Purposes*

KRAS-mutant non-small cell lung cancers (NSCLC) with co-occurring STK11/LKB1 and KEAP1 mutations represent an aggressive subset with poor outcomes and resistance to standard immunotherapy and chemotherapy. These patients urgently need new treatment options. Methods: Researchers screened 20 NSCLC cell lines for sensitivity to ATR inhibitors, validated findings in isogenic cell line models, and tested combinations with chemotherapy and immunotherapy in preclinical models. Clinical validation came from the HUDSON trial analyzing patients treated with ceralasertib plus durvalumab. Key findings include: - Cell lines with STK11/LKB1 and/or KEAP1 mutations showed enhanced sensitivity to ATR inhibitors - LKB1 loss increased replication stress, while KEAP1 mutations activated compensatory ATR-CHK1 signaling - ATR inhibition synergized with gemcitabine and reversed immunosuppressive tumor phenotypes - In the HUDSON trial, patients with STK11/KEAP1 alterations had significantly longer progression-free survival with ceralasertib plus durvalumab (6.0 vs 2.6 months, p=0.008) Conclusions: This work suggests that STK11/LKB1 and KEAP1 alterations could serve as biomarkers for selecting patients who would benefit from ATR inhibitor-based combination therapies. A phase III trial (LATIFY) is currently testing this approach in NSCLC patients who have progressed on immunotherapy and chemotherapy. Paper and research by Ana Galan-Cobo and larger team

Excited to share our latest work on selective autophagy inhibition in cancer: "Small molecule disruption of RARα/NCoR1 interaction inhibits chaperone-mediated autophagy in cancer" Published in EMBO Molecular Medicine https://lnkd.in/eFEpSE5E a collaborative work from Ana Maria Cuervo and Evris Gavathiotis labs Chaperone-mediated autophagy (CMA) is often upregulated in cancers, supporting tumor growth and therapy resistance — yet it has remained undruggable. In this study, we identify NCoR1/RARα interaction as a druggable mechanism and report the first-in-class, selective CMA inhibitor that lead to reduced tumor growth: Key Highlights: -RARα/NCoR1 interaction transcriptionally regulates CMA in NSCLC -CIM7, a novel small molecule, disrupts this complex -CIM7 selectively inhibits CMA (not macroautophagy) -Preferential activity in cancer cells with no observed toxicity -Demonstrates in vivo tumor growth inhibition in NSCLC models This work provides a new pharmacologic strategy to target CMA without broadly impairing lysosomal function — a major step forward for autophagy-based cancer therapies and other conditions driven by abnormal upregulation of CMA. Huge congratulations to Mericka McCabe, PhD for leading this study and to the whole team! Albert Einstein College of Medicine, Montefiore Health System Montefiore Einstein Comprehensive Cancer Center #CancerResearch #Autophagy #CMA #NSCLC #DrugDiscovery #RARalpha #PrecisionMedicine #MolecularMedicine #TargetedTherapy #EMBO

We check PD-L1 expression. We measure TMB. We look for MSI. And still, only 20–40% of patients respond to immune checkpoint inhibitors. What are we missing? This new narrative review (https://lnkd.in/eYgDUu9v ) argues the answer lies in layers of biology we're not yet integrating at the bedside, and that artificial intelligence is the tool to finally fuse them. The review maps how ICI resistance operates across multiple biological dimensions simultaneously: lineage plasticity driven by SOX2/WNT/YAP in NSCLC creates immunosuppressive niches; lactate-driven histone lactylation reinforces T cell suppression through metabolite-to-chromatin feedback loops; gut microbiome composition (including Bacteroides and Prevotella enrichment patterns) modulates systemic ICI responsiveness; and cancer stemness, quantifiable through indices like mRNAsi and CytoTRACE,  correlates with cold, immune-excluded microenvironments across tumor types. The critical insight: AI models integrating these multi-omic layers are already outperforming single biomarkers. A DenseNet-based model combining CT radiomics with inflammatory markers achieved AUCs above 0.86 for ICI response prediction in NSCLC. In DLBCL, an artificial neural network fusing PD-L1 scores, TP53/CREBBP mutations, and spatial immune architecture reached AUCs of 0.94 in independent testing. AI-driven pathomics can predict MSI status directly from histology with AUCs around 0.85,  connecting tissue morphology to molecular programs no pathologist could see alone. But the field's honest bottleneck? Nearly all evidence remains retrospective. Prospective validation, federated learning across diverse populations, and regulatory-grade standardization are the barriers standing between impressive AUCs and clinical utility. For oncologists navigating immunotherapy decisions daily: PD-L1 and TMB were the beginning, not the answer. The future is multi-omic, AI-integrated, and — if we build the right trials — actionable. #Immunotherapy #ArtificialIntelligence #MultiOmics #PrecisionOncology #CancerResearch #CheckpointInhibitors #Microbiome #CancerImmunology #PersonalizedMedicine

🚨 Excited to share our latest in Experimental Hematology & Oncology: “Advancing precision antibody–drug conjugate therapy: unique proteogenomic profiles of tumor subsets in NSCLC” 🔗 https://bit.ly/3IoYHK4 In an era of #ADCs reshaping thoracic oncology, biomarker-driven patient selection is critical. In this study, we performed integrated transcriptomic and proteomic profiling across NSCLC samples and identified four distinct, mutually exclusive subtypes defined by: ◼️ CEACAM5 ◼️ MET ◼️ TACSTD2 (Trop2) ◼️ FOLR1 📌 Key insights: 1. High RNA–protein correlation for these targets, an important finding in era of #RNA NGS 2. Defined targetable subgroups independent of histology or mutation status 3. Framework for biomarker-first ADC development in lung cancer Proud of this collaboration and excited for the future of precision ADC therapy in NSCLC. Vivek Subbiah, MD Rajat Thawani #Oncology #ADC #NSCLC OncoAlert UAB O'Neal Comprehensive Cancer Center International Association for the Study of Lung Cancer